Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myeloid, Acute 148Myelodysplastic Syndromes 116Leukemia 115Precursor Cell Lymphoblastic Leukemia-Lymphoma 95Lymphoma 86Lymphoma, Non-Hodgkin 80Multiple Myeloma 74Hodgkin Disease 68Leukemia, Lymphocytic, Chronic, B-Cell 61Lymphoma, Large B-Cell, Diffuse 52Myeloproliferative Disorders 51Congenital Abnormalities 51Leukemia, Myeloid, Chronic-Phase 50Lymphoma, Follicular 47Leukemia, Myeloid, Accelerated Phase 47Neoplasms, Plasma Cell 46Lymphoma, Mantle-Cell 43Leukemia, Myelomonocytic, Chronic 43Burkitt Lymphoma 42Lymphoma, B-Cell, Marginal Zone 41Lymphoma, Large-Cell, Immunoblastic 39Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Blast Crisis 39Primary Myelofibrosis 36Recurrence 33Anemia, Refractory, with Excess of Blasts 33Hematologic Neoplasms 32Myelodysplastic-Myeloproliferative Diseases 31Graft vs Host Disease 31Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 28

Interventions

Decitabine 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × TP53 × Busulfan × Clear all
NCT04123392 2019-10-10

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown
196 enrolled
Other neoplasm

TP53

Data powered by HemOnc (CC BY 4.0) Colophon âš¡